Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 26;22(1):e137838.
doi: 10.5812/ijpr-137838. eCollection 2023 Jan-Dec.

The Efficacy of High-Dose Pulse Therapy vs. Low-Dose Intravenous Methylprednisolone on Severe to Critical COVID-19 Clinical Outcomes: A Randomized Clinical Trial

Zahra Sahraei  1 , Parnaz Panahi  1 , Kouroush Solhjoukhah  1 , Maryam Mesbah  1 , Siamak Afaghi  2 , Mahdi Amirdosara  3 , Jamshid Salamzadeh  4 , Farzad Esmaeili Tarki  5 , Ilad Alavi Darazam  6
Affiliations

The Efficacy of High-Dose Pulse Therapy vs. Low-Dose Intravenous Methylprednisolone on Severe to Critical COVID-19 Clinical Outcomes: A Randomized Clinical Trial

Zahra Sahraei et al. Iran J Pharm Res. .

Abstract

Background: It remains unclear which formulation of the corticosteroid regimen has the optimum efficacies on COVID-19 pneumonia.

Objectives: The aim of this study was to compare the clinical outcomes of 2 different regimens in the treatment of acute respiratory distress syndrome (ARDS) caused by COVID-19: Methylprednisolone at a dose of 1 mg/kg every 12 hours (low-dose group) and 1000 mg/day pulse therapy for 3 days following 1 mg/kg methylprednisolone every 12 hours (high-dose group).

Methods: In this randomized clinical trial, patients with mild to moderate ARDS due to COVID-19 were randomly assigned to receive either low-dose (n = 47) or high-dose (n = 48) intravenous methylprednisolone regimens. Two groups were matched for age, gender, body mass index (BMI), comorbidities, leukocytes, lymphocytes, neutrophil/lymphocyte, platelet, hemoglobin, and inflammatory markers (erythrocyte sedimentation rate [ESR], C-reactive protein [CRP], and ferritin). Both regimens were initiated upon admission and continued for 10 days. The clinical outcome and secondary complications were evaluated.

Results: Evaluating in-hospital outcomes, no difference was revealed in the duration of intensive care unit (ICU) stays (5.4 ± 4.6 vs. 4.5 ± 4.9; P = 0.35), total hospital stays (8 ± 3.1 vs. 6.9 ± 3.4; P = 0.1), requirement rate for invasive ventilation (29.2% vs. 36.2%; P = 0.4) or non-invasive ventilation (16.6% vs 23.4%; P = 0.4), and hemoperfusion (16.6% vs 11.3%; P = 0.3) between the low- and high-dose groups. There was no significant difference in fatality due to ARDS (29.2% vs. 38.3%; P = 0.3) and septic shock (4.2% vs. 6.4%; P = 0.3) between the low- and high-dose groups. Patients in the high-dose group had significantly higher bacterial pneumonia co-infection events compared with those in the low-dose group (18.7% vs 10.6%; P = 0.01).

Conclusions: The use of adjuvant pulse therapy with intravenous methylprednisolone did not result in improved in-hospital clinical outcomes among patients with mild to moderate ARDS due to COVID-19. A higher risk of bacterial pneumonia should be considered in such cases as receiving a higher dose of steroids.

Keywords: COVID-19; Methylprednisolone; Pulse Therapy; SARS-CoV-2; Steroid.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest.

Figures

Figure 1.
Figure 1.. The CONSORT diagram of the study.
See this image and copyright information in PMC

References

    1. Gharebaghi N, Farshid S, Boroofeh B, Nejadrahim R, Mousavi J, Dindarian S, et al. Evaluation of epidemiology, clinical features, prognosis, diagnosis and treatment outcomes of patients with covid-19 in West Azerbaijan Province. Int J Clin Pract. 2021;75(6):e14108. doi: 10.1111/ijcp.14108. - DOI - PMC - PubMed
    1. Rahimi FS, Afaghi S, Esmaeili Tarki F, Goudarzi K, Malekpour Alamdari N. Viral outbreaks of sars-cov1, sars-cov2, mers-cov, influenza h1n1, and ebola in 21st century; a comparative review of the pathogenesis and clinical characteristics. Sch Med Stud J. 2020;2(3):1–8. doi: 10.22037/smsj.v2i3.30455. - DOI
    1. Al-Dorzi HM, Aldawood AS, Almatrood A, Burrows V, Naidu B, Alchin JD, et al. Managing critical care during covid-19 pandemic: The experience of an ICU of a tertiary care hospital. J Infect Public Health. 2021;14(11):1635–41. doi: 10.1016/j.jiph.2021.09.018. - DOI - PMC - PubMed
    1. Besharat S, Rahimi F, Afaghi S, Esmaeili Tarki F, Pourmotahari F, Fathi M, et al. Chest CT imaging characteristics of covid-19 pneumonia in surviving and non-surviving hospitalized patients: A retrospective study in a referral center in Tehran, Iran. Iran J Radiol. 2021;18(2) doi: 10.5812/iranjradiol.106339. - DOI
    1. Dastan F, Nadji SA, Saffaei A, Tabarsi P. Tocilizumab administration in a refractory case of covid-19. Int J Antimicrob Agents. 2020;56(2):106043. doi: 10.1016/j.ijantimicag.2020.106043. - DOI - PMC - PubMed

LinkOut - more resources